- Treatment for acromegaly is associated with decreases in the prevalence and severity of obstructive sleep apnea syndrome (OSAS).
Why this matters
- Sleep apnea shows increased incidence in patients with acromegaly as a result of craniofacial abnormalities and tissue growth in the upper respiratory tract.
- Treatment for acromegaly was associated with improvements in the Respiratory Disturbance Index (RDI; P=.001), Oxygen Desaturation Index (ODI; P=.001), lowest oxygen saturation (LSaO2; P=.007), and Epworth Sleepiness Scale (ESS; P<.001>
- 30% of analyzed patients with OSAS at baseline were cured of OSAS at 1 year.
- 68.8% of analyzed patients with OSAS at baseline were cured of OSAS at 2.5 years.
- Levels of IGF-1 correlated with OSAS severity (P=.049), and decreases in IGF-1 correlated with improvements in RDI (P<.001 odi lsao>2 (P=.003), and ESS (P<.001>
- 27 patients with treatment-naive acromegaly who received polysomnography; 74.1% diagnosed with OSAS, were included.
- Funding: Ipsen Pharmaceuticals.
- Small patient sample size.